Brief: AnPac Bio-Medical Science Co Ltd Pre-Announced It Has Experienced Strong Growth In Test Volume In First Half Year Of 2021
20/07/2021 13:30
July 20 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* ANPAC BIO-MEDICAL SCIENCE CO LTD - PRE-ANNOUNCED IT HAS
EXPERIENCED STRONG GROWTH IN TEST VOLUME IN FIRST HALF YEAR OF
2021
* ANPAC BIO-MEDICAL SCIENCE CO LTD - TOTAL NUMBER OF PAID
CUSTOMERS AND TESTING VOLUME IN H1 2021 UP ALMOST 110%
* ANPAC BIO-MEDICAL SCIENCE - IN Q2, TOTAL PAID TESTS AND
PAID
CANCER TESTS UP ABOUT 280%, ABOUT 270%, RESPECTIVELY (QUARTER
OVER QUARTER)
* ANPAC BIO-MEDICAL SCIENCE CO LTD - EXPECTS THAT STRONG
TEST
VOLUME GROWTH WILL CONTINUE THROUGHOUT THIS YEAR
Source text for Eikon: ID:nGNX7MtYTr
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022